The first vaccine to prevent cervical cancer has been approved for sale in the European Union. A panel of experts has given the go ahead for Gardasil’s launch before the end of October after large clinical trials have shown a 100 percent efficacy in preventing 4 strains of the disease.
Professor Margaret Stanley of Cambridge University said, “Vaccination with the HPV vaccine Gardasil will have a huge impact on European women.It will reduce dramatically the number of abnormal smears and thus the psychological anxiety that goes with it. It will reduce dramatically the number of surgeries required to remove pre-cancers.”
15,000 women in Europe die each year from cervical cancer. The vaccine is designed to be given to those who are sexually active between the ages of nine to 26, which has cause some controversy.
But trials suggest that vaccinating all 12 years-olds could cut deaths by 75 percent.